Why the study?
Preclinical studies showed ginsenosides may protect against cancer therapeutics-related cardiac dysfunction, but clinical evaluation was needed.
Does Panax ginseng prevent doxorubicin-induced decline in left ventricular ejection fraction in women with non-metastatic breast cancer?
Population
30 women with non-metastatic breast cancer and LVEF ≥ 50%
Comparison
Ginseng (1 g/day) vs placebo besides standard chemotherapy
Design
Randomized, double-blind, placebo-controlled clinical trial
Follow-up
After the eighth chemotherapy cycle
Key result
Prophylactic ginseng (1 g/day) significantly improved left ventricular ejection fraction compared to placebo after eight chemotherapy cycles (mean difference 8.1%, p<0.001) in breast cancer patients.
Authors
Loading...
Ginseng may reduce early CTRCD risk during anthracycline therapy; extends preclinical signals but requires larger RCTs before practice change.
RCT (n=30)
double-blind
1:1 ratio
Does Panax ginseng prevent doxorubicin-induced decline in left ventricular ejection fraction in women with non-metastatic breast cancer?
Mean Difference: 8.1
Absolute Event Rate: 0.8% vs -7.3%
p-value: p=< 0.001
Prophylactic ginseng supplementation significantly attenuated doxorubicin-induced decline in left ventricular ejection fraction in women with non-metastatic breast cancer.
Hamidian et al. (2022) conducted an RCT in non-metastatic breast cancer (n=30). ginseng vs. placebo was evaluated on change in left ventricular ejection fraction (MD 8.1%, p=< 0.001). Prophylactic ginseng (1 g/day) significantly improved left ventricular ejection fraction compared to placebo after eight chemotherapy cycles (mean difference 8.1%, p<0.001) in breast cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: